Breast Cancer Female, HER2-negative Breast Cancer
Conditions
Brief summary
In this study, breast cancer (BC) patients eligible for inclusion will be divided into two groups according to molecular typing and subtyping, which combined immunotherapy and multimodal thermal therapy with conventional neoadjuvant chemotherapy, to explore methods of immune induction for BC, enhance the efficacy of immunotherapy, and accumulate data for subsequent stages of clinical study.
Detailed description
Local tumor destruction with non-surgical ablation (NSA, cryoablation or radiofrequency) induces inflammation and releases antigens that can activate tumor-specific immune responses. Pre-clinically, we demonstrated that multimodal thermal therapy (MTT) as an integrated treatment modality of cryotherapy and radiofrequency heating, can effectively activate systemic and long-lasting antitumor immunity. In this pilot study, patients with operable HER2-negative breast cancer were designed to receive a combination of MTT, immunotherapy and neoadjuvant chemotherapy. Potential favorable intra-tumoral and systemic immunologic effects were assessed with the combination, revealing the possibility for induced and synergistic anti-tumor immunity with this strategy.
Interventions
COMBINATION_PRODUCTDevice: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin
Drugs was given a few days after multimodal thermal therapy
COMBINATION_PRODUCTDevice: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin
Drugs was given a few days after multimodal thermal therapy
Sponsors
Fudan University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Female，age 18-70 years. 2. Histologically confirmed invasive cancer of the breast, and patients meeting cT2-4N+M0 criteria; 3. TNBC non-immunoregulation subtype or HR+/HER2- status were measured by immunohistochemistry (IHC); 4. At least one measurable lesion according to RECIST 1.1 criteria; 5. Normal organ and marrow function: Hemoglobin (HB) ≥90 g/L (No blood was transfused within 14 days), Absolute neutrophil count ≥ 1500/μL, Platelets ≥ 75,000/μL, Total bilirubin ≤ 1.5 x ULN), aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) ≤ 3 x ULN, creatinine \< 1 x ULN, endogenous creatinine clearance \> 50 ml/min (Cockcroft-Gault formula); 6. LVEF ≥55%; 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 8. Non-pregnant and non-lactating, fertile female subjects were required to use a medically approved contraceptive method for the duration of the study treatment and at least 3 months after the last use of the study drug; 9. Ability to understand and willingness to sign a written informed consent.
Exclusion criteria
1. Previous cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any reason; 2. Patients with New York Heart Association (NYHA) grade II or above heart disease (including grade II); 3. Patients with severe systemic infections or other serious diseases; 4. Patients with known allergy or intolerance to the study drug or its excipients; 5. Other malignant tumors in the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer; 6. Pregnant or lactating patients of childbearing age who refused to take appropriate contraceptive measures during the course of the study; 7. Participated in other trial studies within 30 days before the administration of the first dose of the study drug; 8. Endocrine system disorders; 9. Patients who were judged by the investigator to be unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of immune activating response | up to 28 weeks | * Proportion of subjects with immune response to combination therapy detected by biomarkers in peripheral blood samples * Evaluate the infiltration of immune cells in tumor areas and adjacent tissues |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CTCAE scale (V4.0) | up to 28 weeks | To evaluate the rate of adverse effects of patient by the standard CTCAE scale (V4.0) |
Countries
China
Outcome results
None listed